An Integrated View of P53 Dynamics, Function, and Reactivation

Overview

Journal Curr Opin Struct Biol

Date 2021 Jan 5

PMID 33401096

Citations 14

Authors

Ozlem Demir

Emilia P Barros

Tavina L Offutt

Mia Rosenfeld

Rommie E Amaro

Affiliations

Soon will be listed here.

Abstract

The tumor suppressor p53 plays a vital role in responding to cell stressors such as DNA damage, hypoxia, and tumor formation by inducing cell-cycle arrest, senescence, or apoptosis. Expression level alterations and mutational frequency implicates p53 in most human cancers. In this review, we show how both computational and experimental methods have been used to provide an integrated view of p53 dynamics, function, and reactivation potential. We argue that p53 serves as an exceptional case study for developing methods in modeling intrinsically disordered proteins. We describe how these methods can be leveraged to improve p53 reactivation molecule design and other novel therapeutic modalities, such as PROteolysis TARgeting Chimeras (PROTACs).

Citing Articles

How does p53 work? Regulation by the intrinsically disordered domains.

Dyson H, Wright P Trends Biochem Sci. 2024; 50(1):9-17.

PMID: 39578215 PMC: 11698644. DOI: 10.1016/j.tibs.2024.10.009.

STEAP1 regulation and its influence modulating the response of LNCaP prostate cancer cells to bicalutamide, enzalutamide and apalutamide.

Rocha S, Nascimento D, Cardoso A, Passarinha L, Socorro S, Maia C Mol Med Rep. 2023; 27(2).

PMID: 36660947 PMC: 9879076. DOI: 10.3892/mmr.2023.12939.

GCAT: A network model of mutational influences between amino acid positions in PSD95.

Pacini L, Lesieur C Front Mol Biosci. 2022; 9:1035248.

PMID: 36387271 PMC: 9659846. DOI: 10.3389/fmolb.2022.1035248.

Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity.

Chen H, Ho Y, Mezzadra R, Adrover J, Smolkin R, Zhu C Cancer Discov. 2022; 13(2):432-453.

PMID: 36302222 PMC: 9901536. DOI: 10.1158/2159-8290.CD-22-0528.

Nonsense-mediated mRNA decay inhibition synergizes with MDM2 inhibition to suppress TP53 wild-type cancer cells in p53 isoform-dependent manner.

Li Y, Wu M, Zhang L, Wan L, Li H, Zhang L Cell Death Discov. 2022; 8(1):402.

PMID: 36180435 PMC: 9525646. DOI: 10.1038/s41420-022-01190-3.

References

Mujtaba S, He Y, Zeng L, Yan S, Plotnikova O, Sachchidanand . Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol Cell. 2004; 13(2):251-63. DOI: 10.1016/s1097-2765(03)00528-8. View

Loh S . Follow the Mutations: Toward Class-Specific, Small-Molecule Reactivation of p53. Biomolecules. 2020; 10(2). PMC: 7072143. DOI: 10.3390/biom10020303. View

Wassman C, Baronio R, Demir O, Wallentine B, Chen C, Hall L . Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. Nat Commun. 2013; 4:1407. PMC: 3562459. DOI: 10.1038/ncomms2361. View

Morrone J, Perez A, MacCallum J, Dill K . Computed Binding of Peptides to Proteins with MELD-Accelerated Molecular Dynamics. J Chem Theory Comput. 2017; 13(2):870-876. DOI: 10.1021/acs.jctc.6b00977. View

Pettersson M, Crews C . PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future. Drug Discov Today Technol. 2019; 31:15-27. PMC: 6578591. DOI: 10.1016/j.ddtec.2019.01.002. View

Iida S, Kawabata T, Kasahara K, Nakamura H, Higo J . Multimodal Structural Distribution of the p53 C-Terminal Domain upon Binding to S100B via a Generalized Ensemble Method: From Disorder to Extradisorder. J Chem Theory Comput. 2019; 15(4):2597-2607. DOI: 10.1021/acs.jctc.8b01042. View

Herrera-Nieto P, Perez A, De Fabritiis G . Characterization of partially ordered states in the intrinsically disordered N-terminal domain of p53 using millisecond molecular dynamics simulations. Sci Rep. 2020; 10(1):12402. PMC: 7382488. DOI: 10.1038/s41598-020-69322-2. View

Bauer M, Kramer A, Settanni G, Jones R, Ni X, Tareque R . Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm. ACS Chem Biol. 2020; 15(3):657-668. PMC: 7307883. DOI: 10.1021/acschembio.9b00748. View

He F, Borcherds W, Song T, Wei X, Das M, Chen L . Interaction between p53 N terminus and core domain regulates specific and nonspecific DNA binding. Proc Natl Acad Sci U S A. 2019; 116(18):8859-8868. PMC: 6500136. DOI: 10.1073/pnas.1903077116. View

10.

Paul F, Wehmeyer C, Abualrous E, Wu H, Crabtree M, Schoneberg J . Protein-peptide association kinetics beyond the seconds timescale from atomistic simulations. Nat Commun. 2017; 8(1):1095. PMC: 5653669. DOI: 10.1038/s41467-017-01163-6. View

11.

Wang G, Fersht A . Multisite aggregation of p53 and implications for drug rescue. Proc Natl Acad Sci U S A. 2017; 114(13):E2634-E2643. PMC: 5380089. DOI: 10.1073/pnas.1700308114. View

12.

Miller J, Gaiddon C, Storr T . A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer. Chem Soc Rev. 2020; 49(19):6995-7014. DOI: 10.1039/d0cs00163e. View

13.

Emamzadah S, Tropia L, Halazonetis T . Crystal structure of a multidomain human p53 tetramer bound to the natural CDKN1A (p21) p53-response element. Mol Cancer Res. 2011; 9(11):1493-9. DOI: 10.1158/1541-7786.MCR-11-0351. View

14.

Chillemi G, Davidovich P, DAbramo M, Mametnabiev T, Garabadzhiu A, Desideri A . Molecular dynamics of the full-length p53 monomer. Cell Cycle. 2013; 12(18):3098-108. PMC: 3875683. DOI: 10.4161/cc.26162. View

15.

Bykov V, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P . Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002; 8(3):282-8. DOI: 10.1038/nm0302-282. View

16.

Liu X, Tian W, Cheng J, Li D, Liu T, Zhang L . Microsecond molecular dynamics simulations reveal the allosteric regulatory mechanism of p53 R249S mutation in p53-associated liver cancer. Comput Biol Chem. 2019; 84:107194. DOI: 10.1016/j.compbiolchem.2019.107194. View

17.

Bej A, Rasquinha J, Mukherjee S . Conformational Entropy as a Determinant of the Thermodynamic Stability of the p53 Core Domain. Biochemistry. 2018; 57(44):6265-6269. DOI: 10.1021/acs.biochem.8b00740. View

18.

Kussie P, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine A . Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996; 274(5289):948-53. DOI: 10.1126/science.274.5289.948. View

19.

Kannan S, Lane D, Verma C . Long range recognition and selection in IDPs: the interactions of the C-terminus of p53. Sci Rep. 2016; 6:23750. PMC: 4814905. DOI: 10.1038/srep23750. View

20.

Krois A, Dyson H, Wright P . Long-range regulation of p53 DNA binding by its intrinsically disordered N-terminal transactivation domain. Proc Natl Acad Sci U S A. 2018; 115(48):E11302-E11310. PMC: 6275486. DOI: 10.1073/pnas.1814051115. View